Rapport ekes out bipolar mania win as lead asset ‘just hits’ in mid-stage trial

Rapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential pipeline-in-a-product—this time showing improvement in symptoms of bipolar mania.